Device Trial Radar · NCT07151001
Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
935
Actual
Start
Jan 1, 2025
Primary completion
Sep 9, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- iHealthScreen IncNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Sep 2, 2025
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this pivotal trial, the investigators aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.
Conditions
- Diabetes
- Diabetic Retinopathy
Interventions
No interventionDevice
No intervention. Evaluate the automated DR screening software.
Primary outcomes
What the sponsor says the trial is designed to measure.
- mtmDR detected (Referable DR) OR mtmDR not detected (non-referable DR)Time frame: 1-year or 2-year
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
iHealthScreen Inc.
Richmond Hill, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.